Inhibit the JAK pathway* in polycythemia
vera not controlled with hydroxyurea
1-3
Jakafi® (ruxolitinib) is the first and only FDA-approved treatment for patients
who have had an inadequate response to or are intolerant of hydroxyurea3
Jakafi demonstrated superior
results in a phase 3 trial vs best
available therapy3,4†
Primary Response at Week 323,4
80
* Ruxolitinib, a kinase inhibitor, inhibits JAK1 and JAK2
(Janus-associated kinases 1 and 2), which mediate the
signaling of cytokines and growth factors important for
hematopoiesis and immune function.3
A randomized, open-label, active-controlled phase 3 trial
comparing Jakafi with best available therapy (BAT) in
222 patients. Best available \